Literature DB >> 8786988

Regioselectivity and enantioselectivity of metoprolol oxidation by two variants of cDNA-expressed P4502D6.

D S Mautz1, D D Shen, W L Nelson.   

Abstract

PURPOSE: The oxidative metabolism of metoprolol was investigated in two human lymphoblastoma cell-lines transfected with variants of cDNA for cytochrome P4502D6.
METHODS: The regioselective and enantioselective features of the oxidations of deuterium-labeled pseudoracemic metoprolol were characterized by GC/MS analysis of the substrate and products.
RESULTS: There were significant differences between the two P4502D6 variants in the formation kinetics of O-demethylmetoprolol and alpha-hydroxymetoprolol. The h2D6-Val microsomes highly favored the formation of the O-demethylmetoprolol regioisomer 6.3:1 and 2.8:1, respectively from (R)-metoprolol-d0 and (S)-metoprolol-d2, while the corresponding ratios for h2D6v2 microsomes were much lower. For both variants, O-demethylmetoprolol formation favored the (R)-substrate 1.5 to 2-fold, while alpha-hydroxymetoprolol formation was non-enantioselective. Similar Km values of metoprolol oxidation, 10-20 microM, were observed for the two microsomal preparations.
CONCLUSIONS: The regioselectivity, enantioselectivity, and Km values for the h2D6-Val microsomes resemble those observed for the native P4502D6 in human liver microsomes, whereas the h2D6v2 microsomes deviated remarkably in regioselectivity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8786988     DOI: 10.1023/a:1016233115443

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population.

Authors:  J A Agúndez; M C Ledesma; J M Ladero; J Benítez
Journal:  Clin Pharmacol Ther       Date:  1995-03       Impact factor: 6.875

2.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

Authors:  S V Otton; H K Crewe; M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

3.  Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol.

Authors:  S S Murthy; H U Shetty; W L Nelson; P R Jackson; M S Lennard
Journal:  Biochem Pharmacol       Date:  1990-10-01       Impact factor: 5.858

4.  Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6.

Authors:  D S Mautz; W L Nelson; D D Shen
Journal:  Drug Metab Dispos       Date:  1995-04       Impact factor: 3.922

5.  Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

Authors:  H Yokota; S Tamura; H Furuya; S Kimura; M Watanabe; I Kanazawa; I Kondo; F J Gonzalez
Journal:  Pharmacogenetics       Date:  1993-10

6.  Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6.

Authors:  B W Penman; J Reece; T Smith; C S Yang; H V Gelboin; F J Gonzalez; C L Crespi
Journal:  Pharmacogenetics       Date:  1993-02

7.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

Authors:  L M Distlerath; P E Reilly; M V Martin; G G Davis; G R Wilkinson; F P Guengerich
Journal:  J Biol Chem       Date:  1985-07-25       Impact factor: 5.157

8.  Simultaneous determination of metoprolol and metabolites in urine by capillary column gas chromatography as oxazolidineone and trimethylsilyl derivatives.

Authors:  O Gyllenhaal; K J Hoffmann
Journal:  J Chromatogr       Date:  1984-08-10

9.  Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation.

Authors:  E Matsunaga; T Zeugin; U M Zanger; T Aoyama; U A Meyer; F J Gonzalez
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  1 in total

Review 1.  Significance and challenges of stereoselectivity assessing methods in drug metabolism.

Authors:  Zhuowei Shen; Chuang Lv; Su Zeng
Journal:  J Pharm Anal       Date:  2015-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.